Background: Prenatal adversities can increase the risk and severity of lung diseases. Sex differences play a role in the pathogenesis of such diseases. Little is known about the impact of prenatal adversities on sex-differences in lung health. Aims: Here, we aimed to examine if and how prenatal stress affects the sexual dimorphism of respiratory infections with a strong female bias (Influenza A, IAV) through modulation of lung-resident immunity. Methods: Pregnant C57BL/6 mice were exposed to sound stress on gestational days 9.5, 11.5, 13.5, and 15.5. 8 weeks after birth, male and female offspring were infected with 103 P.F.U. H1N1 IAV. Survival and weight loss were monitored and mice were sacrificed on day 3, 6 and 14 post infection (dpi) for viral load and immune response assessment. Results: Our findings confirm that the infection course, based on weight loss and mortality, is more severe in female offspring unexposed to prenatal stress, compared to non-stressed male offspring. Strikingly, a reduced morbidity and mortality was observed in prenatally stressed female offspring, compared to non-stressed females. In prenatally stressed females, we detected increased lung-infiltrating monocytes, tissue-resident dendritic cells and alveolar macrophages on 3 dpi, along with higher cortisol levels. On 14 dpi, lung inflammation was more efficiently resolved in prenatally stressed female mice compared to non-stressed females. Conclusions: Our data underpin that an adjustment to variable environments occurs specifically in female offspring upon stress challenge, referred to as phenotypic plasticity. The advantage is a reduced risk for influenza infection. Other trade-offs remain to be identified.
Background: Sex differences in the manifestation of respiratory diseases have been reported and attributed to sexually dimorphic immune responses. The role of lung-resident immunity in this context remains elusive. Aims: Here, we aimed to examine the sex differences in lung-resident immunity and the role of sex hormones in this context. Methods: Using flow cytometry, we characterized lung-resident immunity in adult C57BL/6 female and male mice, both before and after hormone modulation approaches, such as ovariectomy, castration or testosterone supplementation in females. Finally, the impact of hormones was also examined using mouse orthotopic lung transplantation. Results: Increased alveolar macrophages and lung-resident monocytes were found in male mice, while female mice exhibited higher lung-resident dendritic cells. Castration reversed these effects, as reduced monocytes and alveolar were detected in castrated compared to control males. Castrated males also exhibited increased B cells compared to control males. Of note, no differences in lung-resident immunity were seen after ovariectomy, while testosterone supplementation of female mice was associated with increased neutrophils and decreased B cells residing in the lung. Sex-mismatched orthotopic lung transplantation supported the impact of androgens on lung-resident immunity, as lungs from female donors exhibited reduced resident B cells after their transplantation into male recipients. Conclusions: Our findings highlight that the sexual dimorphism of lung-resident immunity is modulated by androgen-dependent pathways and set the basis for further studies focusing on sex differences in respiratory immune diseases.
Bepirovirsen achieved a functional cure in 19–20% of nucleos(t)ide analogue (NUC)-treated participants in the phase 3 B-Well trials. These trials enrolled patients with baseline quantitative hepatitis B surface antigen (qHBsAg) levels >100–≤ 3000 IU/mL, but the potential reach of this treatment in routine care remains uncertain. We evaluated 706 patients with chronic hepatitis B monoinfection at a German tertiary-care center. qHBsAg levels were ≤100, >100–≤1000, >1000–≤3000, and >3000 IU/mL in 145/706 (20.5%), 175/706 (24.8%), 142/706 (20.1%), and 244/706 (34.6%) patients, respectively. Overall, 317/706 (44.9%) patients fell within the B-Well qHBsAg window. Of these, 109/317 (34.4%) were receiving NUC therapy; among the remaining 208 untreated patients, 23/208 (11.1%) met an operationalized EASL 2025 indication for NUC initiation. The primary implementation scenario therefore comprised 132/706 (18.7%) patients. Excluding patients with identifiable B-Well trial exclusion proxies in a sensitivity analysis reduced this number to 102/706 (14.4%). Applying stratum-specific B-Well response rates of 26.0% and 7.3% yielded hypothetical functional cure rates of 17.2% (approximately 23 modeled functional cures) in the primary scenario and 16.1% (approximately 16 modeled functional cures) in the restricted scenario. These findings estimate the potential clinical reach of bepirovirsen and associated hypothetical functional cure outcomes at our center, highlighting the absence of current NUC therapy as a key factor limiting its implementation.